Pharma News

Customised medicines could one day be manufactured to patients' individual needs, with University of East Anglia (UEA) researchers investigating technology to 3D 'print' pills.

The team, including Dr Andy Gleadall and Prof Richard Bibb at Loughborough University, identified a new additive manufacturing method to allow the 3D printing of medicine in highly porous structures, which can be used to regulate the rate of drug release from the medicine to the body when taken orally.

Daiichi Sankyo Company, Limited announced that it has entered into an exclusive licensing agreement (hereinafter, the Agreement) with Esperion Therapeutics, Inc.  to market bempedoic acid, their proprietary oral once-daily drug for the treatment of hypercholesterolemia, in South Korea, Brazil, Taiwan, Hong Kong, Macao, Thailand, Vietnam, Myanmar and Cambodia .

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma.

Pfizer Inc that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyxs lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.

In the middle of the havoc wreaked by second wave of the pandemic, AYUSH-64 has emerged as a ray of hope for the patients of mild and moderate COVID-19 infection. The scientists of reputed research institutions of the country have found that AYUSH 64, a poly herbal formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of Ayush is useful in the treatment of asymptomatic, mild and moderate COVID-19 infection as an adjunct to standard care.

After patients with cancer undergo surgery to remove a tumor and sometimes additional chemotherapy, tools are used to identify patients at highest risk of recurrence. Non-invasive tools to detect microscopic disease are of especially high value. In a new study published in Clinical Cancer Research, a team led by investigators at Massachusetts General Hospital (MGH) has evaluated the first tumor-uninformed test that detects cancer DNA circulating in the blood of patients following treatment.

Covaxin, Indias home-grown COVID-19 vaccine, has been found to neutralise the 617 variant of the deadly virus, White House chief medical adviser and America's top pandemic expert Dr Anthony Fauci said.

Gilead Sciences, Inc announced that in response to the rapid increase in COVID-19 cases in India, the company is providing its voluntary licensing partners with technical assistance, support for the addition of new local manufacturing facilities and the donation of active pharmaceutical ingredient (API) to rapidly scale up production of remdesivir. Remdesivir is approved in India for restricted emergency use for the treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalized with severe disease.

Glenmark  Pharmaceuticals  Limited,  a  research-led,  global  integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union.